Immunological Treatment Options for Locoregionally Advanced Head and Neck Squamous Cell Carcinoma

Schutt, Christopher A.; Bumm, Klaus; Mirandola, Leonardo; Bernardini, Giovanni; Cunha, N. D.; Tijani, Lukman; Nguyen, Diane; Cordero, Joehassin; Jenkins, Marjorie; Cobos, Everardo; Kast, W. Martin; Chiriva‐Internati, Maurizio

doi:10.3109/08830185.2011.637253

Cited by 9 publications

(6 citation statements)

References 77 publications

(117 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although these are potentially new CTA targets for HNSCC immunotherapies, no data is available at present about their expression at the protein level in tumor cells and their immunogenicity in terms of inducing specific CTL responses against HNSCC. Due to the high heterogeneity of this disease, it is likely that effective vaccines will include a panel of CTA target antigens [ 2 ], of which SP17 is an ideal candidate, considering i) its selective expression in tumor cells and ii) its high immunogenicity as shown by our results.…”

Section: Discussionmentioning

confidence: 96%

“…Aggressively arising from the mucosa of the upper aero-digestive tract, HNSCC is classified by sub-site, which include the oral cavity, oropharynx, nasopharynx, hypopharynx and larynx [ 1 , 2 ]. Presently, treatments options for HNSCC are limited.…”

Section: Introductionmentioning

confidence: 99%

“…Thus, the development of novel therapeutic strategies against HNSCC appears a matter of urgency. One promising strategy is immunotherapy, which is more specific than conventional treatment and induces memory responses that could yield long-term tumor immune-surveillance and reduce the incidence of relapses, thus increasing long-term disease-free survival [ 2 ]. In the quest for the development of immunotherapy approaches for cancer, the discovery and validation of specific targets is critical.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The cancer-testis antigen, sperm protein 17, a new biomarker and immunological target in head and neck squamous cell carcinoma

Schutt

Mirandola²,

Figueroa³

et al. 2017

Oncotarget

Self Cite

View full text Add to dashboard Cite

Head and Neck Squamous Cell Carcinoma is a deadly and locally aggressive malignancy that frequently portends a poor prognosis. Since current treatment modalities including surgery, chemotherapy and radiation are heavily debilitating and often result in recurrence intense efforts have been put into the development of novel less toxic and more lasting treatment strategies. Recently, immunotherapy has been proposed as a promising alternative that could potentially meet these requirements.SP17 is a validated cancer-testis antigen in multiple myeloma, ovarian cancer and non-small cell lung cancer. We aim at studying SP17 expression in HNSCC and its immunogenicity as a possible future target for HNSCC therapeutic vaccines.SP17 expression was evaluated in tissue specimens of HNSCC patients and controls. Moreover, SP17 immunogenicity was studied by generating autologous dendritic cells in vitro from the peripheral blood mononucleated cells of HNSCC patients and testing their ability to induce SP17 specific cytotoxic lymphocytes capable of killing autologous tumor cells in vitro. SP17specific immune responses were also evaluated in HNSCC patients as circulating anti-SP17 autoantibodies.SP17 was expressed in HNSCC tissues of HNSCC patients. Autologous dendritic cells pulsed with SP17 antigen induced powerful SP17 MHC class-I restricted, perforin-dependent, cytotoxic T-cells capable of efficiently killing autologous tumor cells in vitro. SP17-specific autoantibodies were detectable in the serum of HNSCC patients irrespective of tumor site or TNM stage.In conclusion, SP17 is an ideal immunotherapeutic target for HNSCC and a potential serological biomarker of the disease.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The cancer-testis antigen, sperm protein 17, a new biomarker and immunological target in head and neck squamous cell carcinoma

Schutt

Mirandola²,

Figueroa³

et al. 2017

Oncotarget

Self Cite

View full text Add to dashboard Cite

show abstract

“…Neck metastasis is an important prognostic factor and perhaps affects survival; in such advanced head and neck squamous cell carcinomas immunotherapy is an emerging therapeutic option. In this regard, the monoclonal antibody cetuximabin conjunction with radiotherapy may improve survival rates of recurrent or metastatic cases ( 39 ).…”

Section: Discussionmentioning

confidence: 99%

Primary intraosseous squamous cell carcinoma arising in dentigerous cyst: Report of 2 cases and review of the literature

et al. 2015

View full text Add to dashboard Cite

Dentigerous cysts are one of the most common odontogenic cysts of the oral cavity. Odontogenic cysts can give rise to a variety of neoplasms. Carcinoma arising in a dentigerous cyst is extremely rare, with a review of literature showing near 30 cases. The present report describes 2 cases of primary intraosseous squamous cell carcinoma originated from a dentigerous cyst. The first one refers to a 57-year old female with a persistent lesion in the left retromolarregion and diagnosed with squamous cell carcinoma originated fromthe incomplete excision of the lower third molar follicle during its surgical extraction. The second case describes the case of an 18-year old male with an impacted upper canine with previous history of infection and swelling of the oral cavity. The histopathological study revealed the malignization of the follicle surrounding the dental crown. These two cases confirmed the importance of the histopathological study of all the tissue samples obtained from surgical procedures. Although the development of a malignant lesion from a dentigerous cyst is rare and its clinical-radiological features are apparently innocuous, this entity should be considered as a differential diagnosis. Key words:Dentigerous cyst, odontogenic cyst, squamous cell carcinoma, primary intraosseous squamous cell carcinoma, odontogenic carcinoma.

show abstract

“…Compared with the traditional chemotherapies, immunotherapy is more specific, generally less toxic and has the potential for inducing memory responses that could provide long-term tumor immune surveillance. Immunotherapy may decrease the incidence of relapses and increase the long-term disease-free survival via continuous elimination of cancer cells by the primed immune system [136]. Immunotherapies can be classified into specific and non-specific immunotherapies.…”

Section: Competitive Environmentmentioning

confidence: 99%

Emerging drugs for head and neck cancer

Wen

Grandis

2015

Expert Opinion on Emerging Drugs

View full text Add to dashboard Cite

Introduction Despite improvements in treatment, survival rates of head and neck squamous cell carcinoma (HNSCC) are stagnant. The existing chemotherapeutic agents are non-selective and associated with toxicities. Combinations of the only the US FDA-approved epidermal growth factor receptor (EGFR)-targeted agent, cetuximab, with chemotherapy or radiation improves overall survival. However, the response rates to cetuximab are modest. Thus, there is an urgent need for new agents that can be safely integrated into current treatment regimens to improve outcome. Areas covered Current EGFR-targeted drugs under clinical development include mAbs and tyrosine kinase inhibitors. The modest efficacy of these drugs implicates intrinsic or acquired resistance. Novel molecular agents inhibiting alternative targets to overcome anti-EGFR resistance in HNSCC are under investigation. Gene therapy and immunotherapy are also promising strategies to improve efficacy and reduce toxicity. Expert opinion To date, only six drugs have been FDA-approved for the treatment of head and neck cancer. Cetuximab is the only approved molecular targeting agent for HNSCC and despite ubiquitous expression of EGFR in HNSCC tumors, clinical responses are limited. Genetic and epigenetic characterization of HNSCC tumors, coupled with improved preclinical models, should facilitate the development of more effective drugs.

show abstract

Immunological Treatment Options for Locoregionally Advanced Head and Neck Squamous Cell Carcinoma

Cited by 9 publications

References 77 publications

The cancer-testis antigen, sperm protein 17, a new biomarker and immunological target in head and neck squamous cell carcinoma

The cancer-testis antigen, sperm protein 17, a new biomarker and immunological target in head and neck squamous cell carcinoma

Primary intraosseous squamous cell carcinoma arising in dentigerous cyst: Report of 2 cases and review of the literature

Emerging drugs for head and neck cancer

Contact Info

Product

Resources

About